The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.

世界正在进入COVID-19大流行的新时代，在这一时代中，越来越需要可靠的抗体测试。为了支持针对用于人群筛查或诊断的血清学部署的决策，我们提供了血清COVID-19测定的详细比较。我们表明，在所选的检测方法中，在不同情况下以及与病毒中和抗体相关时，检测性能存在很大差异。万代ELISA检测针对SARS CoV-2受体结合域的总免疫球蛋白具有最佳的总体特征，可检测疾病不同阶段和严重程度的功能性抗体，包括有可能表明存在保护性抗体的临界值。